Georgia SB 220 Explained: What the Medical Cannabis Expansion Means for Patients

Ready to find a dispensary near you? Budpedia is the verified directory with real menus, live deals, and city-by-city coverage you can trust.

Georgia Just Rewrote Its Medical Cannabis Playbook

On May 12, 2026, Governor Brian Kemp signed SB 220 into law — officially titled the Georgia Putting Patients First Act — and in doing so transformed the state's medical cannabis program from one of the most restrictive in the country into something that might actually serve its patients. The bill had been working through the General Assembly for months, but its final passage and signing mark the single largest expansion of cannabis access in Georgia's history.

For the roughly 25,000 registered patients who have been navigating Georgia's limited low-THC oil program since its inception, the changes are substantial. For the many more patients who had been disqualified by narrow condition requirements or discouraged by the program's limitations, the door just swung open considerably wider.

Here is what changed, what stayed the same, and what it all means for patients on the ground.

The THC Cap Is Gone — Sort Of

The most headline-grabbing change in SB 220 is the removal of Georgia's existing 5% THC concentration cap. Under the old law, medical cannabis products sold through licensed dispensaries could not exceed 5% THC by weight — a threshold so low that many patients reported the products were therapeutically inadequate for managing chronic pain, seizure disorders, and other serious conditions.

SB 220 replaces the percentage-based cap with a cumulative possession limit: patients may now possess up to 12,000 milligrams (12 grams) of total THC at any given time. This is a fundamentally different approach. Rather than restricting the potency of individual products, the law now limits the total amount of THC a patient can have on hand.

What does this mean practically? A patient could now purchase a product containing 50% THC concentration, provided the total THC content across all products in their possession does not exceed 12 grams. For patients managing severe or chronic conditions — the kind of patients Georgia's program was ostensibly designed to help — this is a meaningful improvement that brings available products closer in line with what medical programs in other states offer.

The 12,000mg possession limit also reflects a considered policy choice. It is high enough to accommodate a month's supply for most patients using higher-potency products, but structured enough to maintain regulatory control. Patients and dispensaries will need to track cumulative THC content rather than simply checking concentration percentages.

Vaporization Gets the Green Light for Adults

SB 220 permits vaporization as an approved delivery method for patients over 21. This is significant for several reasons, and it comes with clear boundaries.

Vaporization — using a device to heat cannabis oil or extract to a temperature that produces inhalable vapor without combustion — has long been regarded by many medical professionals as a preferable inhalation method compared to smoking. It offers faster onset of effects than oral products (typically 5 to 15 minutes versus 30 minutes to two hours for edibles and oils), which matters enormously for patients managing breakthrough pain, acute anxiety episodes, or seizure activity.

The 21-and-over restriction is a deliberate carveout. Georgia's program includes pediatric patients, particularly children with severe seizure disorders, and the legislature chose to restrict inhalation methods to adults while keeping oral delivery methods available for all age groups.

Two things vaporization does not include under SB 220: smoking botanical cannabis and cannabis-infused food products. The law explicitly prohibits both. Patients cannot purchase dried flower for smoking, and manufacturers cannot produce cannabis edibles. Georgia's program remains focused on oils, tinctures, capsules, and now vaporizeable extracts. The state is expanding access without opening the door to the full product range seen in states with recreational programs.

New Qualifying Conditions Broaden Patient Access

SB 220 adds two new qualifying conditions to Georgia's medical cannabis program: inflammatory bowel disease (IBD) and lupus. Both are chronic inflammatory conditions with established patterns of symptom management through cannabinoid therapy in other jurisdictions.

Inflammatory bowel disease — which encompasses both Crohn's disease and ulcerative colitis — affects an estimated 3 million American adults. The condition involves chronic inflammation of the digestive tract, producing symptoms including severe abdominal pain, persistent diarrhea, fatigue, and weight loss. Research published in peer-reviewed journals has documented the anti-inflammatory and symptom-management properties of cannabinoids for IBD patients, and medical cannabis programs in states like Illinois, Ohio, and New York have included IBD as a qualifying condition for years.

Lupus, a systemic autoimmune disease that causes the immune system to attack healthy tissue, affects approximately 1.5 million Americans. Symptoms include chronic pain, joint inflammation, fatigue, and organ damage. The addition of lupus reflects a growing recognition of cannabis as a tool for managing autoimmune conditions — a category that Georgia's previous law did not adequately address.

Perhaps equally important is what SB 220 does to existing qualifying conditions. The bill removes the severe or end-stage requirements that previously applied to many conditions on Georgia's list. Under the old framework, a patient with cancer might qualify only if their condition was considered end-stage or if conventional treatments had failed. SB 220 strips away these gatekeeping qualifiers, allowing physicians to recommend medical cannabis earlier in a patient's treatment journey rather than as a last resort.

This philosophical shift — from cannabis as a desperation measure to cannabis as a legitimate treatment option — may ultimately affect more patients than the addition of new conditions.

From "Low THC Oil" to "Medical Cannabis"

In a change that is partly symbolic and partly substantive, SB 220 replaces all statutory references to "low THC oil" with "medical cannabis" throughout Georgia's code. This is more than a naming convention update.

The term "low THC oil" defined and constrained the program from its inception. It signaled to patients, providers, and the public that Georgia's cannabis program was limited, tentative, and deliberately weak. It also created confusion — patients would hear "medical marijuana" in national conversations and then discover that Georgia's version was a fundamentally different, far more restricted product.

The shift to "medical cannabis" aligns Georgia's statutory language with the terminology used by other medical cannabis states and by the broader medical and scientific community. It signals legislative intent to treat the program as a genuine medical program rather than a cautious experiment.

Substantively, the terminology change also clears the way for regulatory updates. Rules written around "low THC oil" may need revision to accommodate the broader product range and higher potency levels that SB 220 permits. The Georgia Access to Medical Cannabis Commission has been given until January 1, 2027, to finalize new testing and packaging rules consistent with the updated law.

What the Commission Needs to Do by January 2027

The Georgia Access to Medical Cannabis Commission — the regulatory body overseeing the state's medical cannabis program — now has a substantial rulemaking agenda ahead of it. SB 220 sets a January 1, 2027, deadline for the Commission to finalize several critical regulatory frameworks.

Testing standards will need updating to reflect the new THC limits and the introduction of vaporization products. The 5% THC cap made testing relatively straightforward; a cumulative possession limit based on total milligrams requires a different approach to product labeling and verification.

Packaging rules will need to accommodate vaporization devices and cartridges, which present different child-safety and labeling challenges than oral oils and tinctures. The Commission will need to establish standards for vaporization hardware that can be sold alongside cannabis extracts.

The expansion is also expected to drive the issuance of additional retail permits. Georgia's current dispensary network has been limited — a consequence of the original program's narrow scope and the limited product range. With more patients qualifying, more products available, and higher-potency options on the menu, the economic case for expanding retail locations strengthens considerably.

What Patients Should Do Right Now

If you are a current Georgia medical cannabis patient, your existing registration remains valid. The changes in SB 220 will be implemented as the Commission finalizes its regulatory updates, so the transition will not be instantaneous. However, several steps are worth taking now.

Review your qualifying condition status. If you were previously told your condition did not meet the severe or end-stage threshold, the removal of those requirements may change your eligibility. Contact your certifying physician to discuss whether you now qualify under the revised criteria.

Talk to your physician about vaporization. If you are over 21 and have been using oral products with slower onset times, discuss whether vaporization might better address your symptom management needs. Your physician can help you evaluate whether faster-onset delivery is appropriate for your condition.

Understand the new possession limits. The shift from a 5% concentration cap to a 12,000mg cumulative THC possession limit changes how you need to think about purchasing and storing your medicine. Keep track of the total THC content across all products you have on hand.

Watch for new product availability. As the Commission finalizes testing and packaging rules, dispensaries will begin stocking higher-potency products and vaporization options. These will roll out over the coming months as manufacturers reformulate and dispensaries update their inventories.

For Patients with IBD or Lupus

If you have inflammatory bowel disease or lupus and are interested in medical cannabis, SB 220 has opened the door. You will need to obtain a certification from a Georgia-licensed physician who is registered with the state's medical cannabis program. The certification process involves a clinical evaluation where your physician confirms your diagnosis and determines that medical cannabis is appropriate for your condition.

The Georgia Access to Medical Cannabis Commission's website maintains a list of registered physicians, and many telemedicine-based certification services operate in the state. Budpedia's dispensary directory can help you locate licensed dispensaries in your area once you have your patient card.

Where Georgia Stands in the National Landscape

Georgia's expansion arrives at a moment when the national medical cannabis landscape is rapidly evolving. With federal rescheduling of cannabis from Schedule I to Schedule III now complete, states have been reassessing their medical programs in the context of a shifting federal framework.

SB 220 positions Georgia somewhere in the middle of the national spectrum. The state now offers meaningfully potent medical cannabis products and an expanded list of qualifying conditions, but it remains more restrictive than programs in states like Florida, Pennsylvania, or Maryland. The prohibition on smokable flower and edibles keeps Georgia's program narrower than most, and the 12,000mg possession limit, while generous for a program that previously capped potency at 5%, is still a tighter framework than what patients in many other states encounter.

For a Deep South state that only legalized any form of cannabis in 2019 and did not see operational dispensaries until years later, though, SB 220 represents a genuine and substantial step forward. Georgia is no longer running the most restrictive medical cannabis program in the region, and for the patients who depend on it, that matters.

The Bottom Line

Georgia's SB 220 is not legalization. It is not recreational cannabis. It does not allow smoking, and it does not allow edibles. What it does is take a medical program that was struggling to serve its patients — hobbled by a THC cap that limited efficacy and condition requirements that excluded people who could benefit — and rebuild it into something closer to functional.

The removal of the 5% THC cap, the introduction of vaporization for adult patients, the addition of IBD and lupus as qualifying conditions, the elimination of severe and end-stage gatekeeping, and the rebranding from "low THC oil" to "medical cannabis" all point in the same direction: Georgia is getting serious about medical cannabis.

For patients, the message is clear. The program you were promised is finally starting to arrive. Pay attention to the Commission's rulemaking through the end of 2026, stay in contact with your certifying physician, and prepare for a medical cannabis experience that looks meaningfully different from what Georgia has offered until now.